Fever,confusion,acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone?

Abstract

Objective:

Clozapine is the gold-standard antipsychotic medication for treatment-refractory schizophrenia (TRS). However, one potentially lethal side effect of clozapine, as with other antipsychotics, is neuroleptic malignant syndrome (NMS) which could present differently in clozapine therapy. ‘Atypical NMS’ is a recognised variant of NMS with less rigidity and delayed elevation of creatine kinase; this variant is associated with clozapine.

Method:

A case from the author’s clinical practice was reviewed.

Results:

A 67-year-old man with TRS was treated with clozapine. Unfortunately, his physical condition deteriorated and he presented with atypical NMS, which initially was treated as presumable urinary tract infection.

Conclusions:

Atypical NMS is associated with clozapine. This case exposes the potential difficulties in diagnosis, and highlights the importance of considering less common diagnoses in acutely unwell psychiatric patients.

Keywords

atypical clozapine neuroleptic malignant syndrome

Get full access to this article

View all access options for this article.

References

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 35: 1–30.

Strawn

Keck

Jr Caroff

SN.

Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870–876.

Gillman

PK.

Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 2010; 25: 1780–1790.

Mann

Caroff

SN.

Pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 1991; 21: 175–180.

Trollor

Chen

Chitty

. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 2012; 201: 52–56.

Caroff

SN.

Neuroleptic malignant syndrome: still a risk, but which patients may be in danger?

Curr Psychiatry 2003; 2: 36–42.

Caroff

Mann

Campbell

EC.

Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000; 30: 314–321.

Patterson

Jennings

JL.

Spiking fever and profuse diarrhea with clozapine treatment [letter]. Am J Psychiatry 1993; 150: 1126.

Druss

Mazure

CM.

Transient fever and hematologic abnormalities during clozapine use [letter]. J Clin Psychopharmacol 1993; 13: 155–156.

10.

Nitenson

Kando

Frankenburg

. Fever associated with clozapine administration [letter]. Am J Psychiatry 1995; 152: 1102.

11.

Pollmächer

Fenzel

Mullington

. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) level. Pharmacopsychiatry 1997; 30: 118–121.

12.

Juul Povlsen

Noring

Fog

. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71: 176–185.

13.

Blum

Mauruschat

Temperaturanstiege und bluteiweißveränderungen unter der therapie mit neuroleptika – unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-derivates Clozapin. Pharmacopsychiatry 1972; 5: 155–169.

14.

Tham

Dickson

RA.

Clozapine-induced fevers and 1-year clozapine discontinuation rate. J Clin Psychiatry 2002; 63: 880–884.

15.

Y-P

Chang

C-K

Hayes

. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 2014; 130(1): 52–60.